Bicycle Therapeutics Plc ADR

BCYCNASDAQ · USD
3.20USD0.00 (+0.63%)
652

Bicycle Therapeutics Plc ADR (BCYC) Covered Calls

Bicycle Therapeutics Plc ADR trades in the Biotechnology industry with an IV Rank of 86.11%, high versus the past year. BCYC's highest covered call setup is the $8.00 strike expiring Mar 19, 2027, sorted by theoretical annualized return. It's 151.57% out of the money with 123 days to expiration, a 153.14% return until expiration, and a 454.45% theoretical annualized return. Across the setups shown, annualized returns run from 99.85% to 454.45% at strikes between $4.00 and $8.00, with 32 to 123 days to expiration, as of Nov 16, 2026.

Read more

Running BCYC covered calls helps you generate income from Bicycle Therapeutics Plc ADR shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BCYC covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If BCYC stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BCYC covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BCYC covered call is worth writing.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase.

2027-03-191238.00151.570.051.20487.00153.14454.45-1.57+0.4111.15
2027-03-191237.00120.130.100.35392.00123.27365.80-3.14+0.23550.25
2026-12-18324.0025.790.051.0087.0027.36312.06-1.57+0.481400.95
2027-03-191236.0088.680.100.45292.0091.82272.49-3.14+0.283770.35
2027-03-191235.0057.230.100.40192.0060.38179.17-3.14+0.304040.30
2027-03-191234.0025.790.250.60107.0033.6599.85-7.86+0.452,2630.35

As of Nov 16, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV Rank86.11% High
  • Market cap (M$)162
  • 52 weeks high-59.13%
  • 52 weeks low4.23%
  • Analyst recommendationBuy
    1.60
  • Target price$9.86
    208.13% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-10-29
  • P/E—
  • Future P/E—
  • EPS (ttm)-2.03
  • EPS growth next 5 years6.75%

As of Nov 16, 2026